Large Cap Healthcare
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
101
Krystal Biotech
KRYS
$10.2B
| $10.2B | $345.82 | 0.25% |
|
102
Axsome Therapeutics
AXSM
$10.2B
| $10.2B | $195.09 | 0.48% |
|
103
The Ensign Group
ENSG
$10.2B
| $10.2B | $175.18 | 1.1% |
|
104
Dr. Reddy's Laboratories
RDY
$10.2B
| $10.2B | $12.25 | 0.41% |
|
105
Bio-Rad Laboratories Class A
BIO
$10.2B
| $10.2B | $381 | 1.69% |
|
106
Globus Medical
GMED
$10B
| $10B | $74.52 | 0.34% |
|
Large Cap Healthcare Stocks at a Glance
Healthcare companies develop drugs, build medical devices, run hospitals and insurers, and supply the systems behind patient care. Demand is largely non-discretionary, but returns hinge on drug-pipeline outcomes, patent lives, and reimbursement policy — a mix of defensive services and high-risk, high-reward research bets.
There are 106 large cap Healthcare stocks — companies in the Healthcare sector with a market cap between $10B and $200B — worth a combined $4.48T.
The largest by market cap are Gilead Sciences (GILD) at $187B, Abbott (ABT) at $175B and Novo Nordisk (NVO) at $171B.
Among institutional investors, CVS Health (CVS) drew the most net new fund positions in Q2 2026: 323 funds opened new positions, taking total fund holders up 194 (10%) quarter-over-quarter.
- Combined market cap: $4.48T across 106 stocks.
- Large Cap: market cap between $10B and $200B.
- Largest constituent: Gilead Sciences (GILD), $187B market cap.
- Most net new fund positions in Q2 2026: CVS Health (CVS), +194 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.